Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Founded in 1999 by seasoned […] Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all ...

BofA lowered the firm’s price target on Teva (TEVA) to $20 from $23 and keeps a Buy rating on the shares. The firm revised lower its FY26 and ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its target price decreased by Bank of America from $23.00 to $20.00 in a note issued to investors on Thursday,Benzinga reports.

In other news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total ...

This week, Teva launched its most ambitious global campaign in years, ‘For Playground Earth,’ a fully integrated marketing push that reaffirms its heritage in outdoor adventure while inviting ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNY – Research Report) yesterday and set a price target of $63.00. The ...

In our previous articles, we reported that the Federal Circuit affirmed the district court’s decision on December 20, 2024 ordering Teva Pharmaceuticals (“Teva”) to delist certain patents ...